扁桃体癌におけるDIAMOND:シスプラチンは不要か?
Emma R Y Zhang1, Ya Juan Zhou2, Melvin L K Chua3
1Division of Medical Sciences, National Cancer Centre Singapore, 30 Hospital Boulevard, Singapore 168583, Singapore; Department of Mathematics, University of California, Los Angeles, 520 Portola Plaza, MS 6363, Los Angeles, CA 90095-1555, USA.
Abstract:
The phase 3 DIAMOND trial conducted in patients with locoregionally advanced nasopharyngeal carcinoma (LA-NPC) reported comparable 3-year failure-free survival rates between a cisplatin-containing versus a cisplatin-free regimen with radiotherapy, in the backbone of induction, concurrent, and adjuvant anti-programmed death-1 (anti-PD-1) therapy.1 Reduced cisplatin-related emesis also improved quality of life. DIAMOND challenges the conventional dogma of concurrent cisplatin-radiotherapy in the treatment of LA-NPC.
関連する概念動画
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...


